Zentiva announce that it have extended strategic partnership with Adalvo, signing a licensing deal for three molecules, within Europe. The products are indicated in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 RON | -1.14% | +4.85% | +18.49% |
1st Jan change | Capi. | |
---|---|---|
+18.49% | 532M | |
+16.31% | 42.32B | |
+15.88% | 21.29B | |
+19.33% | 15.29B | |
+18.71% | 14.36B | |
+52.78% | 12.81B | |
-0.05% | 6.79B | |
-12.24% | 6.58B | |
-8.87% | 5.73B | |
+14.28% | 5.51B |
- Stock Market
- Equities
- SCD Stock
- News Zentiva S.A.
- Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology